Changes at Italy's drug agency AIFA and their implications for the regulator and industry
This article was originally published in SRA
Laura Orlando examines what the changes means for the agency and for the pharmaceutical industry.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.